Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > PDC market $25 billion in 2018, $50 billion in 2026

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Dec 18, 2020 3:02pm

191 Views

Post# 32141807

RE:PDC market $25 billion in 2018, $50 billion in 2026

Both Angiochem and Katana were founded by the same guy, Richard Beliveau.So both are on that list, since Katana is now Thera.

scarlet1967 wrote:

Drug Name Company Therapeutic Area Highest Clinical Phase

Melflufen Oncopeptides Cancer Phase 3

ANG1005 Angiochem Cancer Phase 3

MLB1707 Mainline Bioscience Cancer Phase 2

BT1718 Bicycle Therapeutics Cancer Phase 1

TH1902 Theratechnologies Cancer Pre-Clinical

TH1904 Theratechnologies Cancer Pre-Clinical"